VIBRANT Study of GORE VIABAHN Endoprosthesis Completes Enrollment

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Jan 2, 2008 - W. L. Gore & Associates (Gore) today announced that it has completed patient enrollment in the Gore VIBRANT (GORE VIABAHN Endoprosthesis veRsus bAre Nitinol stenT) Study of comparative treatments for peripheral vascular disease (PVD) of the superficial femoral artery (SFA). The Gore VIBRANT Study is a randomized, prospective, multi-center clinical trial intended to demonstrate patency superiority in the treatment of lesions eight cm or longer with the GORE VIABAHN(R) Endoprosthesis compared to bare nitinol stents. The study enrolled 150 participants at 15 study sites over the course of three years, with patency surveillance via duplex ultrasound at one-, six-, 12-, 24- and 36-month intervals.
full article >> http://www.pharmalive.com/News/index.cfm?articleid=503071&categoryid=21